| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8367734 | ARMSTRONG PHARMS | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
Jan, 2026
(2 years from now) | |
Primatene Mist is owned by Armstrong Pharms.
Primatene Mist contains Epinephrine.
Primatene Mist has a total of 1 drug patent out of which 0 drug patents have expired.
Primatene Mist was authorised for market use on 07 November, 2018.
Primatene Mist is available in aerosol, metered;inhalation dosage forms.
The generics of Primatene Mist are possible to be released after 26 January, 2026.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 07 November, 2018
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
More Information on Dosage
PRIMATENE MIST family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic